Update: All systems go for 2016
With readouts from three clinical trials expected in 2016, next year will be a critical one for Tonix. First will be data from a Phase II study for TNX-201 (R-isomer of isometheptene) in Q116 for episodic tension-type headache (ETTH), which may offer an effective and non-addictive option. Next will be data from a Phase II trial for TNX-102 SL in H116 for post-traumatic stress disorder (PTSD), where current medications have spotty efficacy. Finally, the Phase III for Tonmya (TNX-102 SL) in fibromyalgia should read out in H216, which we suggest has a high chance of success.Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense through the development of potential medical counter-measures. The company's main drug development program is focused on delivering a long-term treatment for posttraumatic stress disorder. The company's primary product candidate, Tonmya, or TNX-102 SL, is a proprietary low-dose cyclobenzaprine sublingual tablet, designed for bedtime administration. TNX-102 SL is also being developed as a treatment for agitation in Alzheimer's disease.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.